CORMEDIX INC. FILES (8-K) Disclosing Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

Edgar Glimpses |

Item 5.07. Submission of Matters to a Vote of Security Holders.

The Company's 2014 annual meeting of stockholders was held on June 25, 2014. At the meeting, stockholders elected the following seven members to the Company's Board of Directors for a term expiring at the annual meeting of stockholders in 2015, based on the following votes:

Member For Withheld Broker Non-Votes Matthew Duffy 10,831,938 2,966,983 0 Michael W. George 13,060,572 738,349 0 Steven Lefkowitz 13,632,077 166,844 0 Taunia Markvicka 13,796,066 2,855 0 Randy Milby 12,603,272 1,195,649 0 Antony E. Pfaffle, M.D. 13,653,317 145,604 0 Cora M. Tellez 13,060,572 738,349 0

At the meeting, stockholders also ratified the appointment of Friedman LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2014. The vote for such ratification was 13,765,181 shares for, 31,740 shares against, 2,000 shares abstaining and no broker non-votes.

Item 8.01. Other Events.

On June 23, 2014, CorMedix issued a press release announcing that the protocol for a planned pivotal Phase 3 study for Neutrolin® for use in hemodialysis patients with a central venous catheter has been finalized.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits Exhibit No. Description 99.1 Press release dated June 23, 2014 2


DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Symbol Name Price Change % Volume
URHG United Res Hldgs Grp Inc 0.01 0.01 64.64 700


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…

CF0005, LLC dba Mesa-Marshall #1-2

MESA Resources, Inc. ("MESA") is sponsoring the development of the oil & gas well completion project "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development…